PLEXIUM
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases. Plexium's platform focuses on the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unraveling the boundless possibilities of true drug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas.
PLEXIUM
Industry:
Biotechnology Health Care Medical Pharmaceutical Therapeutics
Founded:
2018-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.plexium.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
165 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Domain Not Resolving
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Capital Rx
Capital Rx is a healthtech platform that provides pharmacy benefit management solutions.
Castor
Castor offers a cloud-based clinical data platform that simplifies and streamlines clinical trials processes.
Clene Nanomedicine
Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
Curie Therapeutics
Curie Therapeutics is a fully integrated next-generation radiopharmaceutical firm that combines ligand research and radiochemistry experts.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Fimecs
FIMECS is a focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases.
H1.co
H1 provides a health data platform to support the end-to-end therapeutic development process of medical companies and healthcare systems.
Lucy Therapeutics
Lucy Therapeutics is a biotech company providing effective treatments for neurological diseases start with the mitochondria.
Manifold Bio
Manifold Bio is building a protein barcoding platform to bring the power of multiplexed measurement.
NabGen
NabGen develops therapy to overcome pre-existing immunity and re-administration barriers of gene therapies based on adeno-associated virus.
Ophelia
Ophelia offers medication and support for quitting opioids.
Pacylex
Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers.
Pipeline Therapeutics
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.
Priothera
Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Senti Biosciences
Senti Biosciences is a developer of a programmable biology platform for cancer therapies.
STAQ Pharma
STAQ Pharma offers safety, transparency, availability, and quality to compounded medications.
Stoke Therapeutics
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment.
xCures
xCures is an AI-based precision oncology platform that tightly integrates cancer research and care.
Current Advisors List
Current Employees Featured
Founder
Investors List
CRV
CRV investment in Series B - Plexium
RA Capital Management
RA Capital Management investment in Series B - Plexium
Pappas Capital
Pappas Capital investment in Series B - Plexium
DCVC Bio
DCVC Bio investment in Series B - Plexium
SoftBank Vision Fund
SoftBank Vision Fund investment in Series B - Plexium
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series B - Plexium
M Ventures
M Ventures investment in Series B - Plexium
Surveyor Capital
Surveyor Capital investment in Series B - Plexium
Lux Capital
Lux Capital investment in Series B - Plexium
Neotribe Ventures
Neotribe Ventures investment in Series B - Plexium
Key Employee Changes
Date | New article |
---|---|
2022-05-03 | Plexium Appoints Stephen Mullennix as Chief Financial Officer |
2021-11-04 | Plexium Appoints Percival Barretto-Ko as President and Chief Executive Officer |
Official Site Inspections
http://www.plexium.com Semrush global rank: 5.07 M Semrush visits lastest month: 1.62 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago